Rheumatology

📚 01 General Pediatrics • 🎯 34 High-Yield MCQs • Nelson 22nd Edition Standard

Pediatric Rheumatology: General Concepts & Juvenile Idiopathic Arthritis (JIA)

  • Most Common Pediatric Rheumatic Disease: ((QID004)): Juvenile Idiopathic Arthritis (JIA) is the most frequent pediatric rheumatic disorder, defined by chronic arthritis of unknown origin lasting $\ge$6 weeks with onset before 16 years of age.
  • Oligoarticular JIA: ((((QID005)) · ((QID022)))): Most common subtype (40–50%), affecting $\le$4 joints (chiefly knees, ankles, elbows) in young girls (peak 2–4 years). Complication: High risk of asymptomatic chronic anterior uveitis, mandating baseline and serial slit-lamp examinations, strongly driven by ANA positivity. Initial Management: NSAIDs; if inadequate or for functional limits, use intra-articular triamcinolone hexacetonide ((QID008)). Recurrent synovitis after initial response indicates treatment failure requiring escalation to methotrexate, not repeat injections ((QID008)).
  • Polyarticular JIA, RF-Positive: ((QID006)): Involves $\ge$5 joints with symmetrical small joint involvement (MCP, PIP) and morning stiffness. Closely mirrors adult rheumatoid arthritis, occurring predominantly in older girls (>8 years) with positive rheumatoid factor (RF) and anti-CCP antibodies.
  • Systemic-Onset JIA (sJIA / Still's Disease): ((((QID007)) · ((QID012)) · ((QID026)) · ((QID033)))): Characterized by quotidian high-spiking fevers ($\ge$39°C) occurring daily/twice daily, an evanescent salmon-colored macular truncal rash that appears with fever peaks, hepatosplenomegaly, lymphadenopathy, and serositis (pericarditis). Labs: Markedly elevated ferritin, high ESR, but ANA and RF are characteristically negative. Pathophysiology: Autoinflammatory (IL-1 and IL-6 driven). Treatment: NSAIDs/steroids initially; refractory or steroid-dependent cases require biologic therapy targeting IL-1 (e.g., anakinra, canakinumab) or IL-6 (tocilizumab).
  • Macrophage Activation Syndrome (MAS): ((((QID024)) · ((QID026)))): A life-threatening secondary HLH complication of sJIA. Buzzwords: Rapidly dropping platelet count, hyperferritinemia (often >10,000 ng/mL), hypofibrinogenemia, hypertriglyceridemia, transaminitis, and bone marrow hemophagocytosis. Clinical Hallmark: Paradoxically normal or low ESR (due to low fibrinogen consumption) amidst overwhelming systemic inflammation, coupled with high fever, mucosal bleeding, purpura, and multi-organ dysfunction.
  • Enthesitis-Related Arthritis (ERA): ((QID023)): Predominantly affects older boys presenting with asymmetric lower-limb arthritis, enthesitis (tenderness at tendon insertions like the Achilles), and axial/lumbosacral spine involvement. Strongly associated with HLA-B27 positivity and ANA negativity.
  • Psoriatic JIA: ((QID025)): Distinguished by arthritis plus dactylitis (sausage digits), nail pitting/onycholysis, or DIP joint involvement, often with a family history of psoriasis in a first-degree relative.
  • Biologics & DMARDs in JIA: ((((QID002)) · ((QID003)) · ((QID009)) · ((QID010)) · ((QID011)) · ((QID013)))): - First-line DMARD: Methotrexate (MTX) (weekly, folate-supplemented). Toxicity: Megaloblastic macrocytic anemia and dose-dependent hepatotoxicity. - TNF Inhibitors: Etanercept, adalimumab, and golimumab are FDA-approved for polyarticular JIA after MTX failure. Infliximab lacks this specific FDA indication ((QID003)). - Mandatory Pre-Biologic Action: Screen for latent tuberculosis (TST or IGRA) before starting TNF inhibitors due to the risk of granuloma breakdown and TB reactivation ((QID013)). - JAK Inhibitors: Tofacitinib is the sole FDA-approved oral JAK inhibitor for pediatric polyarticular JIA (children $\ge$2 years and $\ge$10 kg) ((QID002)).

Juvenile Dermatomyositis (JDM)

  • Diagnostic Criteria & Cutaneous Hallmarks: ((((QID016)) · ((QID018)) · ((QID034)))): Requires a characteristic rash plus at least three of the following: symmetric proximal muscle weakness, elevated muscle enzymes, characteristic EMG findings, or muscle biopsy showing perifascicular atrophy. - Rashes: Heliotrope rash (violaceous eyelid discoloration with periorbital edema; the most common cutaneous sign) and Gottron papules (violaceous papules over knuckles/extensor joints) ((QID016)).
  • Muscle Enzymes & Markers: ((QID017)): Lactate dehydrogenase (LDH) is the most sensitive continuous marker for active muscle inflammation (often remaining elevated when CK fluctuates or is normal).
  • Myositis-Specific Antibodies & Phenotypes: ((((QID014)) · ((QID015)) · ((QID019)))):
  • Anti-MDA5:: Associated with rapidly progressive interstitial lung disease (ILD) (ground-glass opacities on HRCT), normal CK levels, and severe skin/palmar ulcerations with elevated ferritin.
  • Anti-NXP2:: Predicts severe muscle weakness, prominent calcinosis cutis, and dangerous gastrointestinal vasculopathy/bleeding.
  • Anti-Mi-2:: Classic rash pattern with a generally favorable prognosis and good response to therapy.
  • Management: ((QID020)): Immediate combination therapy with high-dose oral prednisolone (2 mg/kg/day) plus a steroid-sparing agent like methotrexate, alongside aggressive sun protection and calcium/vitamin D supplementation.

Auto-inflammatory, Vasculitic, and Mimicking Conditions

  • Reactive Arthritis (ReA): ((((QID027)) · ((QID028)) · ((QID029)))): Sterile inflammatory arthritis following enteric (Salmonella, Shigella, Yersinia, Campylobacter) or genitourinary (Chlamydia) infections. Features asymmetric lower-limb oligoarthritis, enthesitis, HLA-B27 positivity, and extra-articular manifestations (urethritis, circinate balanitis, keratoderma blennorrhagicum). Chronic cases (>6 months) unresponsive to NSAIDs/steroids require DMARDs (sulfasalazine or methotrexate) ((QID029)).
  • Behçet's Disease: ((((QID031)) · ((QID032)))): Multisystem vasculitis defined by recurrent painful oral aphthous ulcers, genital ulcers, and ocular inflammation (classic anterior uveitis with hypopyon or posterior uveitis). Key associations: HLA-B51 positivity and a positive pathergy test (sterile pustule at needle-prick site). Neuro-Behçet's (presenting with cerebral venous sinus thrombosis/meningoencephalitis) mandates aggressive induction with high-dose IV corticosteroids plus cyclophosphamide ((QID032)).
  • Growing Pains: ((QID021)): Benign intermittent, bilateral lower extremity (calf/thigh) pain occurring exclusively in the evening/night, resolving entirely by morning, with normal physical exam, normal growth, and completely normal inflammatory labs.
  • Transient (Toxic) Synovitis of the Hip: ((QID030)): Most common cause of acute hip pain/limp in children aged 3–10 years, frequently following a viral URI. Characterized by a mild joint effusion, clear sterile aspirate, low-grade/afebrile status, and rapid self-resolution with rest and NSAIDs.